Sarah Robertson, PharmD., is the Team Leader for Antiviral Drug Products in the Office of Clinical Pharmacology at the Center for Drug Evaluation and Research (CDER), U.S. FDA. Dr. Robertson received a B.S. in chemistry from Marquette University, followed by her Doctorate of Pharmacy from the University of Wisconsin at Madison.After completing a pharmacy practice residency at Northwestern Memorial Hospital in Chicago, she completed a two-year Clinical Pharmacokinetics Research Fellowship at the NIH, where her research and clinical practice focused on HIV and the pharmacology of antiretrovirals. Dr. Robertson began working for the FDA in 2006, and has worked with both anti-infective and antiviral drug products. In her current position, Dr. Robertson and her team support the Office of New Drugs in all aspects of drug development related to the clinical pharmacology of antiviral drugs, from early Phase 1 studies through post-approval. Dr. Robertson is a member of the NIH-CDC-HIVMA/IDSA Committee on the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV. Dr. Robertson volunteers at a community non-profit Hepatitis C clinic in Maryland, where she also sits on the Board of Directors.